NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS
Post# of 101
(Total Views: 99)
Posted On: 06/18/2024 5:03:37 PM
NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Officials to Present Results from Alzheimer’s Study at AAIC 2024
Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), will be presenting results from its latest Alzheimer’s study at the Alzheimer’s Association International Conference(R) 2024 (“AAIC”). The conference is slated to run from July 28–Aug. 1, 2024, in Philadelphia as well as online. According to the announcement, Annovis Bio senior VP of research & development Dr. Cheng Fang will present an extended 45-minute session at the conference; the presentation is scheduled to begin at 8 a.m. on July 31. He will be joined by Kathleen A. Welsh-Bohmer, PhD, a professor in psychiatry and neurology at Duke University, and Maria L. Maccecchini, PhD, Annovis Bio founder and president. Titled “Data from Phase 2/3 Clinical Study in Mild to Moderate Alzheimer’s Disease,” the presentation will include an overview of significant findings from the company’s recent studies of Buntanetap in patients with mild AD as well an in-depth look at the drug’s efficacy and safety in both APOE4 carriers and noncarriers. A premier global forum for the latest advancements in dementia research, AAIC gathers together scientists from around the world to share their findings, discuss new ideas and foster collaborations. “We look forward to sharing the details of our phase 2/3 results with the scientific community at this prominent conference,” said Annovis Bio senior VP of research & development Dr. Cheng Fang in the press release. “We are also grateful for the 45-minute format, which allows us to present our data comprehensively.”
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at http://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), will be presenting results from its latest Alzheimer’s study at the Alzheimer’s Association International Conference(R) 2024 (“AAIC”). The conference is slated to run from July 28–Aug. 1, 2024, in Philadelphia as well as online. According to the announcement, Annovis Bio senior VP of research & development Dr. Cheng Fang will present an extended 45-minute session at the conference; the presentation is scheduled to begin at 8 a.m. on July 31. He will be joined by Kathleen A. Welsh-Bohmer, PhD, a professor in psychiatry and neurology at Duke University, and Maria L. Maccecchini, PhD, Annovis Bio founder and president. Titled “Data from Phase 2/3 Clinical Study in Mild to Moderate Alzheimer’s Disease,” the presentation will include an overview of significant findings from the company’s recent studies of Buntanetap in patients with mild AD as well an in-depth look at the drug’s efficacy and safety in both APOE4 carriers and noncarriers. A premier global forum for the latest advancements in dementia research, AAIC gathers together scientists from around the world to share their findings, discuss new ideas and foster collaborations. “We look forward to sharing the details of our phase 2/3 results with the scientific community at this prominent conference,” said Annovis Bio senior VP of research & development Dr. Cheng Fang in the press release. “We are also grateful for the 45-minute format, which allows us to present our data comprehensively.”
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at http://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)Anv Sec Group Inc. (ANVS) Stock Research Links
Scroll down for more posts ▼